Leslie M. Randall
Advanced in Lump in the Abdomen

Dr. Leslie M. Randall

Capital Womens Care LLC
Rockville, MD
Advanced
in Lump in the Abdomen
Specialties:Gynecologic Oncology | Obstetrics and Gynecology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Leslie Randall is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Rockville, Maryland. Dr. Randall and is rated as an Advanced provider by MediFind in the treatment of Lump in the Abdomen. Her top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Hysterectomy. Dr. Randall is currently accepting new patients.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in VA
Hospital Affiliations
Community Memorial Hospital
Medical College Of Virginia Hospitals
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Oscar
  •  Humana
  •  Piedmont

Locations

CAPITAL WOMENS CARE LLC
9711 Medical Ctr Dr, Suite 320, Rockville, MD 20850
301-330-5401
Other Locations
CAPITAL WOMENS CARE LLC
3023 Hamaker Ct, 210a, Fairfax, VA 22031
703-698-8060
CAPITAL WOMENS CARE LLC
15225 Shady Grove Rd, Suite 306, Rockville, MD 20850
301-869-7644
CAPITAL WOMENS CARE LLC
2301 Research Blvd, Suite 215, Rockville, MD 20850
301-424-3444
CAPITAL WOMENS CARE LLC
9420 Key W Ave, Suite 415, Rockville, MD 20850
301-279-9400

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib in Combination With Pembrolizumab in Black Participants With Mismatch Repair-Proficient Recurrent Endometrial Cancer
A Multicenter, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib in Combination With Pembrolizumab in Black Participants With Mismatch Repair-Proficient Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Cisplatin, Carboplatin, Paclitaxel, Atezolizumab
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 2
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Enrollment Status: Unknown
Publish Date: April 25, 2022
Intervention Type: Biological
Study Drugs: AVOVA-1, MC
Study Phase: Phase 2
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Procedure, Device, Drug
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I Dose-escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment in Patients With Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas.
A Phase I Dose-escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment in Patients With Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas.
Enrollment Status: Completed
Publish Date: January 31, 2020
Intervention Type: Drug
Study Phase: Phase 1
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 22, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 11 Less Clinical Trials

68 Total Publications

Progress in the treatment paradigms for locally advanced cervical cancer.
Progress in the treatment paradigms for locally advanced cervical cancer.
Journal: Lancet (London, England)
Published: August 30, 2024
Similar Doctors
Expertise in
34
conditions
Dr. Charles R. Boice
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
34
conditions
Dr. Charles R. Boice
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Medstar Medical Group Ii LLC

9000 Franklin Square Dr, 
Baltimore, MD 
 (42.2 mi)
443-777-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Boice is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Boice and is rated as a Distinguished provider by MediFind in the treatment of Lump in the Abdomen. His top areas of expertise are Cervical Cancer, Malignant Mixed Mullerian Tumor, Neuroendocrine Carcinoma of the Cervix, Salpingo-Oophorectomy, and Oophorectomy. Dr. Boice is currently accepting new patients.

Expertise in
45
conditions
Dr. Dwight D. Im
Gynecologic Oncology | Oncology
Expertise in
45
conditions
Dr. Dwight D. Im
Gynecologic Oncology | Oncology

St Paul Place Specialists Inc

301 Saint Paul St, 
Baltimore, MD 
 (34.0 mi)
Languages Spoken:
English
See accepted insurances

Dwight Im is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Im and is rated as a Distinguished provider by MediFind in the treatment of Lump in the Abdomen. His top areas of expertise are Rectocele, Angiomyoma, Uterine Fibroids, Hysterectomy, and Oophorectomy.

Expertise in
40
conditions
Dr. Teresa P. Diaz-Montes
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
40
conditions
Dr. Teresa P. Diaz-Montes
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

St Paul Place Specialists Inc

7602 Belair Rd, 
Baltimore, MD 
 (40.7 mi)
410-663-8100
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Teresa Diaz-Montes is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Diaz-Montes and is rated as a Distinguished provider by MediFind in the treatment of Lump in the Abdomen. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Vulvar Cancer, Hysterectomy, and Ureteroscopy. Dr. Diaz-Montes is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile